This segment focuses on the development and commercialization of AditxtScore™, a platform designed to provide individuals with a comprehensive understanding of their immune profiles. The technology utilizes a multiplexed assay to measure various immune markers, offering insights into immune system activity and potential risks. Research and development efforts are directed towards expanding the panel of measurable markers and improving the accuracy and reliability of the platform. The goal is to empower individuals and healthcare providers with actionable information for personalized health management, early disease detection, and optimized treatment strategies. Future opportunities include expanding the application of AditxtScore™ to various disease areas and integrating it with telemedicine platforms for remote monitoring and consultation.

This segment is dedicated to the development of Apoptotic DNA Immunotherapy (ADi™), a novel nucleic acid-based technology that mimics the body's natural mechanisms for inducing tolerance to its own tissues. The approach involves utilizing apoptotic DNA to reprogram the immune system and prevent or reverse autoimmune reactions. Research and development activities are focused on optimizing the ADi™ technology for various applications, including organ transplantation, autoimmune diseases, and allergies. The therapeutic areas covered include psoriasis. The aim is to develop targeted therapies that can modulate the immune system and provide long-term benefits for patients with immune-related disorders. Future opportunities include exploring the potential of ADi™ in combination with other immunomodulatory agents and expanding its application to other autoimmune conditions.